- Home
- ALXO vs ORGN Comparison
ALXO vs ORGN Comparison
Compare ALXO & ORGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- ORGN
- Stock Information
- Founded
- ALXO 2015
- ORGN 2008
- Country
- ALXO United States
- ORGN United States
- Employees
- ALXO N/A
- ORGN N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- ORGN Major Chemicals
- Sector
- ALXO Health Care
- ORGN Industrials
- Exchange
- ALXO Nasdaq
- ORGN Nasdaq
- Market Cap
- ALXO 93.7M
- ORGN 109.4M
- IPO Year
- ALXO 2020
- ORGN N/A
- Fundamental
- Price
- ALXO $1.26
- ORGN $0.53
- Analyst Decision
- ALXO Strong Buy
- ORGN
- Analyst Count
- ALXO 6
- ORGN 0
- Target Price
- ALXO $3.30
- ORGN N/A
- AVG Volume (30 Days)
- ALXO 424.8K
- ORGN 1.5M
- Earning Date
- ALXO 11-07-2025
- ORGN 11-13-2025
- Dividend Yield
- ALXO N/A
- ORGN N/A
- EPS Growth
- ALXO N/A
- ORGN N/A
- EPS
- ALXO N/A
- ORGN N/A
- Revenue
- ALXO N/A
- ORGN $28,667,000.00
- Revenue This Year
- ALXO N/A
- ORGN $49.18
- Revenue Next Year
- ALXO N/A
- ORGN $144.81
- P/E Ratio
- ALXO N/A
- ORGN N/A
- Revenue Growth
- ALXO N/A
- ORGN N/A
- 52 Week Low
- ALXO $0.40
- ORGN $0.40
- 52 Week High
- ALXO $2.27
- ORGN $1.38
- Technical
- Relative Strength Index (RSI)
- ALXO 38.76
- ORGN 42.53
- Support Level
- ALXO $1.49
- ORGN $0.58
- Resistance Level
- ALXO $1.64
- ORGN $0.75
- Average True Range (ATR)
- ALXO 0.14
- ORGN 0.06
- MACD
- ALXO -0.05
- ORGN -0.02
- Stochastic Oscillator
- ALXO 4.13
- ORGN 8.55
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About ORGN Origin Materials Inc.
Origin Materials Inc is a carbon-negative materials company. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include, PET circular caps and closures, Para-xylene, carbon black, Levulinic acid among others by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.